CG Oncology, Inc. (CGON)
BuyA data-driven read of CGON's strengths and risk factors, built from its financials, earnings history, analyst activity, and insider trading, not opinion or speculation.
Five independent market signals, analysts, institutions, insiders, short sellers, and price trend, each scored from real, current data. See exactly where the smart money agrees, and where it's split.
All 5 available signals lean the same direction: bullish.
Every trading day in the last 2 years where CGON moved 4% or more in a single session, most recent first, a quick read on how volatile this stock has really been. See full daily price history →
| Date | Move | Close |
|---|---|---|
| Aug 28, 2026 | -5.91% | $74.34 |
| Aug 19, 2026 | +4.63% | $80.68 |
| Jul 30, 2026 | +5.66% | $73.03 |
| Jul 29, 2026 | -4.82% | $69.12 |
| Jul 27, 2026 | +6.06% | $73.52 |
| Jul 16, 2026 | -4.79% | $69.50 |
| Jul 9, 2026 | +5.04% | $73.32 |
| Jun 25, 2026 | +6.00% | $72.84 |
| Jun 24, 2026 | +4.55% | $68.72 |
| Jun 22, 2026 | +8.46% | $66.25 |
| Jun 11, 2026 | +4.95% | $57.64 |
| Jun 9, 2026 | +4.17% | $56.67 |
| Jun 5, 2026 | -4.23% | $53.72 |
| Jun 2, 2026 | -6.25% | $55.53 |
| Jun 1, 2026 | -4.91% | $59.23 |
| May 18, 2026 | -5.98% | $62.93 |
| May 14, 2026 | -6.03% | $69.54 |
| Apr 20, 2026 | -4.13% | $70.40 |
| Apr 17, 2026 | +10.69% | $73.43 |
| Mar 31, 2026 | +5.82% | $67.68 |
| Mar 18, 2026 | -6.10% | $64.45 |
| Mar 17, 2026 | +4.16% | $68.64 |
| Mar 3, 2026 | +4.83% | $60.55 |
| Feb 27, 2026 | +4.79% | $58.80 |
| Feb 17, 2026 | +4.60% | $53.87 |
Showing the 25 most recent of 104 on record. Full history is on the Price Insights page.
Every major event from the past 12 months, earnings reports, insider transactions, and analyst upgrades or downgrades, merged into a single chronological feed so you can see what clustered together.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
3000 Pegasus Park Drive, Dallas, TX, 75247, United States, 949 409 3700
Other Biotechnology companies tracked on this site, ranked by institutional ownership. Compare CGON against its closest peers.
A complete statistical profile built from CGON's full price, financial, and ownership history, not an isolated snapshot. Explore any category in depth below.